Drugs / Volociximab
Volociximab
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00782093 | Oct 2008 → Jun 2012 | age-related macular degeneration | Ophthotech Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00666692 | Apr → Oct 2008 | non-small cell lung carcinoma | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00654758 | Dec 2007 → May 2010 | non-small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00635193 | Jul 2007 → Oct 2008 | ovarian cancer | AbbVie | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00516841 | Aug 2007 → Apr 2008 | ovarian cancer, peritoneal neoplasm | Facet Biotech | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00369395 | Dec 2006 → Mar 2008 | melanoma | Abbott | Terminated | No outcome recorded |
| Phase 2 | NCT00278187 | Jul 2005 → ? | lung cancer | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 2 | NCT00401570 | Mar 2005 → Jun 2008 | malignant pancreatic neoplasm | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00100685 | Jan 2005 → Dec 2007 | metastatic neoplasm, renal cell carcinoma | Abbott | Terminated | No outcome recorded |
| Phase 2 | NCT00099970 | Dec 2004 → Mar 2006 | melanoma, metastatic neoplasm | PDL BioPharma, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-01-08 | Biogen | Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech biogen.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Volociximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00100685 ↗ |
| Known as | M200 | “M200 (volociximab) in Combination with Dacarbazine (DTIC)” NCT00099970 ↗2“Volociximab (M200) in Combination With Gemcitabine” NCT00401570 ↗ “M200 (Volociximab)” NCT00635193 ↗ |
| Known as | Volociximab (M200) | “Volociximab (M200)” NCT00666692 ↗1“Volociximab (M200)” NCT00654758 ↗ |
| Action | Inhibit | “Volociximab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor.” NCT00278187 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin)” NCT00099970 ↗ |
| Route | Intravenous | “administered intravenously” NCT00100685 ↗ |